Trial ID or NCT#

NCT00911508

Status

not recruiting iconNOT RECRUITING

Purpose

The (Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial) CABANA Trial has the overall goal of establishing the appropriate roles for medical and ablative intervention for atrial fibrillation (AF). The CABANA Trial is designed to test the hypothesis that the treatment strategy of left atrial catheter ablation for the purpose of eliminating atrial fibrillation (AF) will be superior to current state-of-the-art therapy with either rate control or rhythm control drugs for decreasing the incidence of the composite endpoint of total mortality, disabling stroke, serious bleeding, or cardiac arrest in patients with untreated or incompletely treated AF.

Official Title

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Eligibility Criteria

Ages Eligible for Study: 18 Years to 90 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Paul  J. Wang, MD
Paul J. Wang, MD
Cardiac electrophysiologist
John R. and Ai Giak L. Singleton Director, Professor of Medicine (Cardiovascular Medicine) and, by courtesy, of Bioengineering

Contact us to find out if this trial is right for you.

CONTACT

Gerri O’Riordan
(650) 725-5597